## **Online Supplement**

## Appendix Figure. Flow chart for the study sample

Prescribers with  $\geq 1$  antipsychotic (AP) prescription in the Pennsylvania Medicaid program

- 2010: n = 10,610 (treating 120,443 patients)
- 2011: n = 10,546 (treating 122,691 patients)
- 2012: n = 10,174 (treating 116,922 patients)

Exclude AP prescriptions for patients ≥65 or <18, or Medicare dual eligibles. N prescribers:

• 2010: n = 1,168

• 2011: n = 1,105

2012: n = 1.075

Prescribers writing AP prescriptions to patients aged 18-64 years and not dually eligible for Medicare

- 2010: n = 9,442 (treating 85,164 patients)
- 2011: n = 9,441 (treating 88,097 patients)
- 2012: n = 9,099 (treating 85,352 patients)

Exclude AP prescriptions for patients without a diagnosis of schizophrenia. N prescribers:

• 2010: n = 5,946

- 2010: n = 5,940 • 2011: n = 6,198
- 2012: n = 6,042

Prescribers writing AP prescriptions to patients with schizophrenia

- 2010: n = 3,496 (treating 16,243 patients)
- 2011: n = 3,243 (treating 15,236 patients)
- 2012: n = 3,057 (treating 15,102 patients)

Exclude AP prescribers with ≤9 patients with schizophrenia

- 2010: n = 2,851
- 2011: n = 2,611
- 2012: n = 2,407

Prescribers writing AP prescriptions to  $\geq\!\!10$  patients with schizophrenia

- 2010: n = 645 (treating 14,072 patients)
- 2011: n = 632 (treating 13,606 patients)
- 2012: n = 650 (treating 13,559 patients)

## Appendix Table 1. ICD-9 codes for several comorbidities

Diagnosis	ICD-9 codes		
Affective disorders	296, 300.4, 301.13, 309.1, 311		
Anxiety disorders	300.0, 309.81, 300.2, 300.3		
Other psychiatric disorders	307.1, 307.50, 307.51, 314		
Substance use disorders	291, 292, 303, 304, 305.0, 305.2-305.7, 305.9		
Brain/cognitive impairment comorbidity	331, 797, 290, 294, 310, 317-319		

Appendix Table 2. Prescribers' clozapine and polypharmacy practices by their patient caseloads with schizophrenia-related hospitalization (quartiles), 2010-2012

Share of patient caseloads with schizophrenia-related hospitalization	Any clozapine prescribing, %	Any polypharmacy prescribing, %	Share of patients w/ clozapine use, % (M±SD)	Share of patients w/ polypharmacy use, % (M±SD)		
Year 2010						
1st quartile (0.0-24.7%)	46	61	5±7	7±8		
2nd quartile (25.0-36.0%)	60	67	7±12	8±8		
3rd quartile (36.1-53.3%)	58	69	7±9	7±8		
4th quartile (53.8-100.0%)	60	29	5±7	2±4		
Year 2011						
1st quartile (0.0-25.6%)	58	77	7±10	9±9		
2nd quartile (25.8-38.5%)	68	76	9±12	10±9		
3rd quartile (38.9-61.1%)	59	61	7±11	7±8		
4th quartile (61.4-100.0%)	56	24	5±8	2±4		
Year 2012						
1st quartile (0.0-25.0%)	61	73	9±12	10±9		
2nd quartile (25.5-37.3%)	63	75	7±10	9±8		
3rd quartile (37.5-60.0%)	60	63	6±10	8±9		
4th quartile (60.7-100.0%)	57	20	5±6	2±5		